Home|Journals Follow on Twitter| Subscribe to List

Directory for Medical Articles
 

Open Access

1

Natl J Med Res. 2015; 5(3): 185-189


A Prospective Study of Estrogen, Progestrone & Her2Neu Receptor in Cases of Breast Cancer in A Tertiary Care Hospital of Bhavnagar, Gujarat, Western India

Tejas N Hathila, Ravi B Sangle, Shrut A Doshi, Dekhaiya A Firdaus, Mihir P Rupani.

Abstract
Introduction: Hormonal receptors in breast have an implication on the outcomes of breast cancer in women. The objectives of the study were to know the incidence and therapeutic importance of ER/PR & HER2NEU receptor status and itís relation to recurrence in breast cancer cases.
Methodology: A prospective study was conducted over a period of two years from 2012-2013 on 30 newly diagnosed cases of breast cancer admitted at a tertiary care centre in Bhavnagar. Patientswere clinically staged and either posted for surgery or for neo-adjuvant chemotherapy. In case they were posted for Modified Radical Mastectomy, the specimen of the breast tissue was sent to histo-pathological examination and immuno-histochemistry to determine the ER, PR & HER2NEU receptor status of the breast specimen. On basis of clinical and histo-pathological staging, patient receivedchemotherapy and hormonal therapy. Patients were then monitored for recurrence of breast cancer.
Results: The present study found 53.3% breast cancer patients positive for ER, 36.6% patients positive for PR, 53.3% co-positive for ER/PR and 56.6% patients positive for HER2NEU receptor. Breast cancer patients 50 years of age were 25.6 times more likely to test positive for HER2NEU receptors. ER/PR negative patients (who are conventionally not treated with Tamoxifen) were 28.6 times more likely to experience recurrence of breast cancer at six months than EP/PR positive patients who are treated with Tamoxifen. HER2NEU receptor positive patients were 5.2 times more likely to experience recurrence of breast cancer than HER2NEU receptor negative patients.
Conclusion: Post-operative recurrence issignificantly less in ER/PR positive breast cancer patients who are treated with Tamoxifen hormonal therapy and is significantly high in HER2NEU receptor positive patients.

Key words: Breast cancer, Estrogen receptor, Progesterone receptor, HER2NEU receptor, Tamoxifen



Share this Article


Advertisement
American Journal of Physiology, Biochemistry and Pharmacology

SUBMIT YOUR ARTICLE NOW


ScopeMed.com
ScopeMed Home
Follow ScopeMed on Twitter
BiblioCAM
Author Tools
eJPort Journal Hosting
About ScopeMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMedģ Information Services.
Scopemed Buttons